ATE139701T1 - Zusammensetzung zur herabsetzung der nebenwirkungen eines arzneimittels - Google Patents

Zusammensetzung zur herabsetzung der nebenwirkungen eines arzneimittels

Info

Publication number
ATE139701T1
ATE139701T1 AT90905767T AT90905767T ATE139701T1 AT E139701 T1 ATE139701 T1 AT E139701T1 AT 90905767 T AT90905767 T AT 90905767T AT 90905767 T AT90905767 T AT 90905767T AT E139701 T1 ATE139701 T1 AT E139701T1
Authority
AT
Austria
Prior art keywords
drug
side effects
reducing
composition
medicinal product
Prior art date
Application number
AT90905767T
Other languages
English (en)
Inventor
Kenneth Naoyuki Matsumura
Original Assignee
Kenneth Naoyuki Matsumura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth Naoyuki Matsumura filed Critical Kenneth Naoyuki Matsumura
Application granted granted Critical
Publication of ATE139701T1 publication Critical patent/ATE139701T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2204—Bleomycin hydrolase (3.4.22.40)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT90905767T 1989-03-13 1990-03-08 Zusammensetzung zur herabsetzung der nebenwirkungen eines arzneimittels ATE139701T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32220989A 1989-03-13 1989-03-13

Publications (1)

Publication Number Publication Date
ATE139701T1 true ATE139701T1 (de) 1996-07-15

Family

ID=23253890

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90905767T ATE139701T1 (de) 1989-03-13 1990-03-08 Zusammensetzung zur herabsetzung der nebenwirkungen eines arzneimittels

Country Status (7)

Country Link
EP (1) EP0464135B1 (de)
CN (1) CN1032190C (de)
AT (1) ATE139701T1 (de)
AU (1) AU5349290A (de)
CA (1) CA2055497A1 (de)
DE (1) DE69027598T2 (de)
WO (1) WO1990010460A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
DE69333266T2 (de) * 1992-03-23 2004-07-15 Matsumura, Kenneth N., Berkeley Zusammensetzung zur verminderung von nebenwirkungen eines arzneimittels
CH687062A5 (de) * 1994-02-14 1996-09-13 Cerbios Pharma Sa Konzentrierte Injektionsloesung von Alkalimetallsalzen von reduzierten Folaten.
NL9400530A (nl) 1994-04-05 1995-11-01 Pharmachemie Bv Stabiele waterige folinaatoplossing.
US20100166848A1 (en) * 2007-09-11 2010-07-01 Joseph Ciccolini Liposomal formulations for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
AU573193B2 (en) * 1982-11-23 1988-06-02 Bio-Response Inc. Method for isolating cells
EP0153955A1 (de) * 1983-09-06 1985-09-11 Health Research, Inc. Verfahren zum verabreichen von liposomen zum herabsetzen der toxizität eines antitumor-arzneimittels
IL86009A (en) * 1987-04-10 1991-09-16 Us Health Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases
US5112954A (en) * 1988-02-26 1992-05-12 Neorx Corporation Method of enhancing the effect of cytotoxic agents

Also Published As

Publication number Publication date
AU5349290A (en) 1990-10-09
DE69027598D1 (de) 1996-08-01
EP0464135B1 (de) 1996-06-26
CN1046464A (zh) 1990-10-31
EP0464135A4 (en) 1992-04-01
CN1032190C (zh) 1996-07-03
WO1990010460A1 (en) 1990-09-20
EP0464135A1 (de) 1992-01-08
CA2055497A1 (en) 1990-09-14
DE69027598T2 (de) 1996-10-31

Similar Documents

Publication Publication Date Title
FI892016A0 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten, mahdollisesti -substituoitujen 4-(-kinolin-2-yyli-metoksi)-fenyylietikkahappojen ja -esterien valmistamiseksi
EP0337256A3 (de) Verfahren zur Herstellung pharmazeutischer Mischungen
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
AT400296B (de) Dosierungsform zur schnellen abgabe eines wirkstoffes gefolgt von einer langsamen abgabe eines wirkstoffes
DE3588095D1 (de) Polypeptid, dessen Verfahren zur Herstellung und dieses enthaltende pharmazeutische Zusammensetzung und deren Benutzung
ES2173858T3 (es) Analogos de huperzina a.
SE7902742L (sv) Disubstituerade 3-cefem-4-karboxylsyraderivat samt forfarande for framstellning derav
ES2054177T3 (es) Derivados disubstituidos del acido (quinolin-2-il-metoxi)fenilacetico.
ATE139701T1 (de) Zusammensetzung zur herabsetzung der nebenwirkungen eines arzneimittels
FR2581382B1 (fr) Derives n-(quinolyl) glycinamides, leur procede de preparation et leur application therapeutique en tant que psychotropes
AT382076B (de) Verfahren zur herstellung von presslingen mit retardierter wirkstofffreisetzung
YU108691A (sh) Nove 3,3'-ditiobis (propionske kiseline) i njihovi estri
DE69333266D1 (de) Zusammensetzung zur verminderung von nebenwirkungen eines arzneimittels
FI98309B (fi) Menetelmä synteettisten isohirudiinien valmistamiseksi, joilla on parantunut stabiilisuus
DE3862017D1 (de) Pharmazeutische zubereitung zur behandlung von tinea pedis.
JPS5728031A (en) Ethylenediamine derivative and medicinal composition as effective component thereof
ES2045366T3 (es) Procedimiento para la preparacion de l-fosfinotricina.
AT344885B (de) Verfahren zur herstellung von 18-arabinosyl-2-n-butyl-3,7,11,15,19,21,23,25,27,37-dekahydroxy-4,16,32,34,36-pentamethyl-tetrakonta-16,32-dien-35-o-lacton-40-guanidiniumsulfat(debrycin) enthaltenden pharmazeutischen praeparaten
ES2081279T3 (es) Utilizacion de 15-desoxiespergualina como medicamento.
SE8002244L (sv) Nytt 1alfa,25-dihydroxi-cholekalciferolderivat, sett for framstellning samt anvendning derav som lekemedel och farmaceutiska kompositioner inehallande denna forening
AT342761B (de) Verfahren zur herstellung von homopyrimidazol-derivate enthaltenden, stabilen pharmazeutischen praparaten zur oralen verabreichung
ATE53384T1 (de) 3-mercapto-2-oxo-1-pyrrolidinessigsaeurederivate verfahren zur herstellung und pharmazeutische zusammensetzungen die sie enthalten.
ATE16809T1 (de) Verwendung eines aus blutserum gewonnenen wirkstoffes zur stabilisierung von prostaglandinen.
RU93058659A (ru) Способ снижения побочных эффектов лекарства
PT76773A (en) Process for the preparation of an aqueous pharmaceutical composition with salbutamol base

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee